The Importance of Monitoring Myeloma Markers

In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “The Underrepresented Majority”, which highlighted the lack of access to some of the basic anti-myeloma drugs in LMICs and the resulting disparity in global outcomes. 

Here are some of the sections discussed in this episode:

03:33 Diagnostic workup of myeloma in LMICs

15:46 Induction therapy for new diagnosed transplant-eligible myeloma

27:17 Early Transplant vs Delayed Transplant in the Context of LMICs

33:11 Maintenance therapy 

37:27 Management of relapsed myeloma

Affordability of novel drugs in myeloma: https://pubmed.ncbi.nlm.nih.gov/29461639/

45:30 Clinical Trials in LMICs. Is industry exploiting patients in LMICs?

Article by Dr. Gómez-De León in Lancet Haematology:  https://pubmed.ncbi.nlm.nih.gov/36174637/